TLZ-16-CL

N/A

Report date: 2023/01/01 11:30:52
NME

Base Information

Drug NameTLZ-16-CL
Drug Alias NameTLZ-16-CL
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsSubstance Withdrawal SyndromeCocaine-Related Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Taizhou Lize Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Taizhou Lize Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSubstance Withdrawal SyndromeCocaine-Related Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A